Fluorodeoxyglucose uptake in laryngeal carcinoma is associated with the expression of glucose transporter‑1 and hypoxia‑inducible‑factor‑1α and the phosphoinositide 3‑kinase/protein kinase B pathway

Zhao,Kui; Yang,Shu‑Ye; Zhou,Shui‑Hong; Dong,Meng Jie; Bao,Yang‑Yang; Yao,Hong‑Tian

doi:10.3892/ol.2014.1877

Fluorodeoxyglucose uptake in laryngeal carcinoma is associated with the expression of glucose transporter‑1 and hypoxia‑inducible‑factor‑1α and the phosphoinositide 3‑kinase/protein kinase B pathway

Authors:
- Kui Zhao
- Shu‑Ye Yang
- Shui‑Hong Zhou
- Meng Jie Dong
- Yang‑Yang Bao
- Hong‑Tian Yao
View Affiliations

Affiliations: Department of PET Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China, Department of Otolaryngology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China, Department of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China
Published online on: February 12, 2014 https://doi.org/10.3892/ol.2014.1877
Pages: 984-990

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

High fluorodeoxyglucose (FDG) uptake by human carcinomas, including head and neck cancers, is associated with a poor prognosis. Glucose transporter‑1 (Glut‑1) is believed to be an intrinsic marker of hypoxia in malignant tumors. The expression of hypoxia‑inducible factor‑1α (HIF‑1α) and correlated target genes, including Glut‑1, is regulated by the phosphoinositide 3‑kinase/protein kinase B (PI3K/Akt) pathway. However, it remains unclear whether the PI3K/Akt signaling pathway is involved in regulating FDG uptake directly. In the present study, 24 consecutive patients with laryngeal carcinoma were examined pre‑operatively and the standardized uptake values (SUV) of the laryngeal carcinomas were determined. Glut‑1, HIF‑1α, PI3K and phosphorylated‑Akt (p‑Akt) expression was detected by immunohistochemical staining of paraffin sections from the tumor specimens. Associations among SUVmax, Glut‑1, HIF‑1α, PI3K and p‑Akt protein expression and the other clinical parameters were analyzed. The univariate analyses revealed a significantly shorter survival time along with higher HIF‑1α (P=0.018) and PI3K (P=0.008) expression, but the survival time was not significantly correlated with Glut‑1 or p‑Akt expression. The multivariate analysis demonstrated that higher SUVmax (P=0.043) and PI3K expression (P=0.012) were significantly correlated with a poor survival time. Spearman's rank analysis showed significant correlations between SUVmax and HIF‑1α (r=0.577; P=0.003), PI3K (r=1.0; P<0.0001) and p‑Akt (r=0.577; P=0.003) expression. PI3K was associated with poorly‑ and moderately‑differentiated laryngeal carcinoma (P=0.012). In conclusion, a high SUVmax indicates a poor prognosis for laryngeal carcinoma. Also, a high SUVmax may be associated with the increased expression of Glut‑1, HIF‑1α, PI3K and p‑Akt.

View Figures

View References

1	Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF and Subramaniam RM: 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med. 53:709–715. 2012.
2	Kaira K, Okumura T, Ohde Y, et al: Correlation between 18F-FDG uptake on PET and molecular biology in metastatic pulmonary tumors. J Nucl Med. 52:705–711. 2011. View Article : Google Scholar : PubMed/NCBI
3	Zhao K, Luo XM, Zhou SH, et al: ⁽¹⁸⁾F-Fluorodeoxyglucose positron emission tomography/computed tomography as an effective diagnostic workup in cervical metastasis of carcinoma from an unknown primary tumor. Cancer Biother Radiopharm. 27:685–693. 2012. View Article : Google Scholar
4	Hentschel M, Paulus T, Mix M, Moser E, Nitzsche EU and Brink I: Analysis of blood flow and glucose metabolism in mammary carcinomas and normal breast: a H2(15)O PET and 18F-FDG PET study. Nucl Med Commun. 28:789–797. 2007. View Article : Google Scholar : PubMed/NCBI
5	Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009.PubMed/NCBI
6	Zhou S, Wang S, Wu Q, Fan J and Wang Q: Expression of glucose transporter-1 and -3 in the head and neck carcinoma - the correlation of the expression with the biological behaviors. ORL J Otorhinolaryngol Relat Spec. 70:189–194. 2008. View Article : Google Scholar : PubMed/NCBI
7	Esen Akkas B, Gökaslan D, Güner L and Ilgin Karabacak N: FDG uptake in brown adipose tissue-a brief report on brown fat with FDG uptake mechanisms and quantitative analysis using dual-time-point FDG PET/CT. Rev Esp Med Nucl. 30:14–18. 2001.
8	Prante O, Maschauer S, Fremont V, et al: Regulation of uptake of 18F-FDG by a follicular human thyroid cancer cell line with mutation-activated K-ras. J Nucl Med. 50:1364–1370. 2009. View Article : Google Scholar : PubMed/NCBI
9	Han MW, Lee HJ, Cho KJ, et al: Role of FDG-PET as a biological marker for predicting the hypoxic status of tongue cancer. Head Neck. 34:1395–1402. 2012. View Article : Google Scholar : PubMed/NCBI
10	Li XF, Ma Y, Sun X, Humm JL, Ling CC and O’Donoghue JA: High 18F-FDG uptake in microscopic peritoneal tumors requires physiologic hypoxia. J Nucl Med. 51:632–638. 2010. View Article : Google Scholar : PubMed/NCBI
11	Alakus H, Batur M, Schmidt M, et al: Variable 18F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression. Nucl Med Commun. 31:532–538. 2010.PubMed/NCBI
12	Nagamatsu A, Umesaki N, Li L and Tanaka T: Use of 18F-fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas. Oncol Rep. 23:1069–1076. 2010.PubMed/NCBI
13	Luo XM, Zhou SH and Fan J: Glucose transporter-1 as a new therapeutic target in laryngeal carcinoma. J Int Med Res. 38:1885–1892. 2010. View Article : Google Scholar : PubMed/NCBI
14	Rademakers SE, Lok J, van der Kogel AJ, Bussink J and Kaanders JH: Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer. 11:1672011.PubMed/NCBI
15	Kaira K, Serizawa M, Koh Y, et al: Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. Eur J Cancer. 48:1244–1254. 2012. View Article : Google Scholar
16	Izuishi K, Yamamoto Y, Sano T, et al: Molecular mechanism underlying the detection of colorectal cancer by 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography. J Gastrointest Surg. 16:394–400. 2012. View Article : Google Scholar
17	Robey IF, Stephen RM, Brown KS, Baggett BK, Gatenby RA and Gillies RJ: Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia. 10:745–756. 2008.
18	Bos R, van Der Hoeven JJ, van Der Wall E, et al: Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 20:379–387. 2002. View Article : Google Scholar
19	Machtay M, Natwa M, Andrel J, et al: Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck. 31:195–201. 2009. View Article : Google Scholar
20	Li LF, Zhou SH, Zhao K, et al: Clinical significance of FDG single-photon emission computed tomography: Computed tomography in the diagnosis of head and neck cancers and study of its mechanism. Cancer Biother Radiopharm. 23:701–714. 2008. View Article : Google Scholar : PubMed/NCBI
21	Zimny M, Gagel B, DiMartino E, et al: FDG - a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging. 33:1426–1431. 2006.
22	Gagel B, Piroth M, Pinkawa M, et al: pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer. 7:1132007.PubMed/NCBI
23	Shen WQ, Cheng KJ, Bao YY, Zhou SH and Yao HT: Expression of Glut-1, HIF-1α, PI3K and p-Akt in a case of ceruminous adenoma. Head Neck Oncol. 4:182012.
24	Shafee N, Kaluz S, Ru N and Stanbridge EJ: PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines. Cancer Lett. 282:109–115. 2009. View Article : Google Scholar
25	Morani F, Pagano L, Prodam F, Aimaretti G and Isidoro C: Loss of expression of the oncosuppressor PTEN in thyroid incidentalomas associates with GLUT1 plasmamembrane expression. Panminerva Med. 54:59–63. 2012.
26	Fang J, Luo XM, Yao HT, Zhou SH, Ruan LX and Yan SX: Expression of glucose transporter-1, hypoxia-inducible factor-1α, phosphatidylinositol 3-kinase and protein kinase B (Akt) in relation to [(18)F]fluorodeoxyglucose uptake in nasopharyngeal diffuse large B-cell lymphoma: a case report and literature review. J Int Med Res. 38:2160–2168. 2010.
27	Bae JS, Roh JL, Lee SW, et al: Laryngeal edema after radiotherapy in patients with squamous cell carcinomas of the larynx and hypopharynx. Oral Oncol. 48:853–858. 2012. View Article : Google Scholar : PubMed/NCBI
28	Haerle SK, Schmid DT, Ahmad N, Hany TF and Stoeckli SJ: The value of (18)F-FDG PET/CT for the detection of distant metastases in high-risk patients with head and neck squamous cell carcinoma. Oral Oncol. 47:653–659. 2011. View Article : Google Scholar : PubMed/NCBI
29	Schinagl DA, Span PN, Oyen WJ and Kaanders JH: Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study. Eur J Nucl Med Mol Imaging. 38:1449–1458. 2011. View Article : Google Scholar
30	Tian M, Zhang H, Nakasone Y, Mogi K and Endo K: Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl Med Mol Imaging. 31:5–12. 2004. View Article : Google Scholar : PubMed/NCBI
31	Fang J, Bao YY, Zhou SH, et al: Recurrent prognostic factors and expression of GLUT-1, PI3K and p-Akt in adenoid cystic carcinomas of the head and neck: Clinicopathological features and biomarkers of adenoid cystic carcinoma. Oncol Lett. 4:1234–1240. 2012.PubMed/NCBI
32	Melstrom LG, Salabat MR, Ding XZ, et al: Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas. 37:426–431. 2008. View Article : Google Scholar : PubMed/NCBI
33	Ahn KJ, Hwang HS, Park JH, et al: Evaluation of the role of hexokinase type II in cellular proliferation and apoptosis using human hepatocellular carcinoma cell lines. J Nucl Med. 50:1525–1532. 2009. View Article : Google Scholar : PubMed/NCBI
34	Burrows N, Babur M, Resch J, et al: GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1α (HIF-1α) pathways. J Clin Endocrinol Metab. 96:E1934–E1943. 2011.PubMed/NCBI